Dianthus Therapeutics
DNTH
93 hedge funds and large institutions have $139M invested in Dianthus Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 16 closing their positions.
0.02% more ownership
Funds ownership: 5.07% → 5.09% (+0.02%)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 94 → 93 (-1)
34% less capital invested
Capital invested by funds: $211M → $139M (-$72.5M)
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$6.02M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.46M |
| 3 |
Millennium Management
New York
|
+$2.46M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$1.82M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.67M |
Top Sellers
DNTH Hedge Fund Activity: Q1 2022 in Review
93 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2022, worth a combined $139M — down 34% from $211M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of DNTH and 15 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 19 added.
The largest buyer was Janus Henderson Group, adding an estimated $6.02M. The largest seller was Aquilo Capital Management, exiting entirely with an estimated $14M sold.
- 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2022, down from 94 in Q4 2021.
- Funds reported $139M of Dianthus Therapeutics stock for Q1 2022, down 34% quarter-over-quarter.
- 15 funds opened new Dianthus Therapeutics positions in Q1 2022 and 16 closed out, a net change of -1 holder.
- The largest Dianthus Therapeutics buyer in Q1 2022 was Janus Henderson Group, an estimated $6.02M added.
- The largest Dianthus Therapeutics seller in Q1 2022 was Aquilo Capital Management, an estimated $14M sold.
Based on aggregated 13F filings for Q1 2022.